Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer: A single-institution outcome study

Chemotherapy

Volumn 54, Issue 5, 2008, Pages 395-403

  Matsumoto, Shigemi ^a   Nishimura, Takafumi ^a   Kanai, Masashi ^a   Mori, Yukiko ^a   Nagayama, Satoshi ^a   Kawamura, Jun'Ichiro ^a   Nomura, Akinari ^a   Miyamoto, Shin'Ichi ^a   Kitano, Toshiyuki ^a   Ishiguro, Hiroshi ^a   Yanagihara, Kazuhiro ^a   Teramukai, Satoshi ^a   Sakai, Yoshiharu ^a   Chiba, Tsutomu ^a   Fukushima, Masanori ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 Fluorouracil; Colorectal cancer; FOLFOX regimen; Leucovorin; Oxaliplatin

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GLUCONATE CALCIUM; IRINOTECAN; MAGNESIUM SULFATE; OXALIPLATIN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; HYPONATREMIA; ILEUS; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG TOXICITY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 51049096390     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000154921     Document Type: Article

References (31)

1. Center for Cancer Control and Information Services, National Cancer Center, Japan. http://ganjoho.ncc.go.jp/professional/statistics/statistics. html#01 (accessed 15 November 2007).
2. NCCN Clinical Practice Guidelines in Oncology™: Colon cancer. V.II.2007. http://www.nccn.org/ (accessed 30 April 2008).
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
4. De Gramont A, Figer A, Seymour M, Homerin M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
5. Maindrault-Goebel F, Louvet C, Andre T, Carola E, et al: Oxaliplatin added to the simplified bimonthly leucovorin and fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999;35:1338-1342.
6. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
7. Cheeseman SL, Joel SP, Chester JD, et al: A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002;87:393-399.
8. Braun MS, Adab F, Bradley C, et al: Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. Br J Cancer 2003;89:1155-1158.
9. Grothey A: Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003;30(suppl 15):5-13.
10. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006;20:394-400.
11. Matsumoto S, Nishimura T, Kanai M, et al: Development of a novel information technology (IT) system using the electronic medical record (EMR) in daily clinical practice (abstract). J Clin Oncol 2007;25(suppl 18S):17066.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 2000;92:205-216.
13. Gamelin L, Boisdron-Celle M, Delva R, et al: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10:4055-4061.
14. Andre T, Louvet C, Maindrault-Goebel F, et al: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-1347.
15. National Cancer Institute: The Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. http://ctep.cancer.gov/reporting/index.html.
16. Campbell M, Grothey A, Sargent D, et al: Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741 (abstract). J Clin Oncol 2007;25(suppl 18S):4080.
17. Bajetta E, Di Bartolomeo M, Buzzoni R, et al: Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer 2007;96:439-444.
18. Komatsu Y, Yuki S, Iwanaga I, et al: Phase II clinical study of combination therapy with irinotecan and S-1 (IRIS) for inoperable recurrent advanced colorectal cancer (2nd report): for Hokkaido Gastrointestinal Cancer Study Group (HGCSG) (abstract). J Clin Oncol 2007;25(suppl 18S):4105.
19. Tsavaris N, Koamas C, Skopelitis H, et al: Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study. Chemotherapy 2007:53;282-291.
20. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559-1565.
21. Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-3616.
22. Sutanto-Ward E, Arisawa Y, Tremiterra S, Sigurdson ER: Regional chemotherapy for colorectal hepatic metastases: evidence for improved survival with new drug combinations. Ann Surg Oncol 1996;3:36-43.
23. De Gramont A, Buyse M, Abrahantes JC, et al: Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007;25:3224-3229.
24. Maindrault-Goebel F, Lledo G, Chibaudel B, et al: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study (abstract). J Clin Oncol 2007;25(suppl 18S):4013.
25. Hochster HS, Grothey A, Shpilsky A, Childs BH: Effect of intravenous calcium and magnesium versus placebo on response to FOLFOX + bevacizumab in the CONcePT trial. Gastrointestinal Cancers Symposium, Orlando, January 2008, abstract 280.
26. Maindrault-Goebel F, Andre T, Tournigand C, et al: Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005;41:2262-2267.
27. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
28. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
29. Grothey A, Sugrue M, Hedrick E, et al: Association between exposure to bevacizumab beyond first progression and overall survival in patients with metastatic colorectal cancer: results from a large observational study (BRiTE) (abstract). J Clin Oncol 2007;25(suppl 18S):4036.
30. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
31. Popov I, Jelic S, Krivokapic Z, et al: What is the best sequence of chemotherapy in advanced colorectal cancer? Final results of a five-arm study. Chemotherapy 2006;52:20-22.